Provided by Tiger Fintech (Singapore) Pte. Ltd.

SciSparc Ltd.

0.3750
+0.03008.70%
Post-market: 0.3462-0.0288-7.68%19:52 EDT
Volume:358.19K
Turnover:129.95K
Market Cap:4.06M
PE:-0.07
High:0.3802
Open:0.3495
Low:0.3475
Close:0.3450
Loading ...

Company Profile

Company Name:
SciSparc Ltd.
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
3
Office Location:
Tower A,2nd Floor,20 Raul Wallenberg Street,Tel Aviv,Israel
Zip Code:
6971916
Fax:
- -
Introduction:
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Directors

Name
Position
Ascher Shmulewitz
Chairman of the Board of Director and Interim Chief Executive Officer
Amit Berger
Director
Eric So
Director
Stephen M. Simes
Director
Yafit Stark
Director
Zohar Heiblum
Director

Shareholders

Name
Position
Ascher Shmulewitz
Chairman of the Board of Director and Interim Chief Executive Officer
Oz Adler
Chief Financial Officer
Adi Zuloff Shani
Chief Technologies Officer